BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Marvel Biosciences Initiates Formulation Development with Catalent

  Catalent, one of the world’s largest contract research organizations, has begun development of novel solid amorphous dispersion formulations of MB-204, the Company’s novel adenosine A2a receptor antagonist.

  April 6, 2022

   · 

  5 min read
• Bloodstream Infection Testing Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2026

  The report further provides details about each segments and regions covered in the global Bloodstream Infection Testing market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

  April 6, 2022

   · 

  7 min read
• Biotech Beach

  CB Scientific, Inc. Announces Uplist to the OTCQB(R) Venture Market

  CB Scientific. Inc., a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, announces its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market.

  April 6, 2022

   · 

  3 min read
• Business

  Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment

  OMass Therapeutics is pleased to announce that its founder, Professor Dame Carol Robinson and her team, published a paper in Nature1 on the 6th of April.

  April 6, 2022

   · 

  4 min read
• Business

  Aspect Biosystems Announces Partnership with JDRF to Advance Development of a Bioengineered Tissue Therapeutic to Treat Type 1 Diabetes

  Aspect Biosystems (“Aspect”), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

  April 6, 2022

   · 

  2 min read
• Pharvaris to Participate in Upcoming April 2022 Investor Conferences

  Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema, announced that management will participate in two upcoming investor conferences in April.

  April 6, 2022

   · 

  1 min read
• BioForest

  Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 06, 2022

  Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

  April 6, 2022

   · 

  1 min read